Clear Street Initiates Coverage On Evommune with Buy Rating, Announces Price Target of $53

Clear Street analyst Kaveri Pohlman has initiated coverage on Evommune (NYSE: EVMN) with a Buy rating. The analyst has set a price target of $53 for the stock.